Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 12/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 10/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641960 | 0.84 | CYP1A2 (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL12064816 | 0.83 | CYP1A2 (0.54) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL967958 | 0.83 | CA2 (0.50) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL968880 | 0.83 | HTR1A (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8510380 | 0.83 | CA2 (0.50) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL1568273 | 0.82 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7628613 | 0.80 | SIGMAR1 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL407503 | 0.79 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL10645332 | 0.79 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL2108392 | 0.79 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044225-A1 | Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives | MILLENNIUM PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2001092249-A3 | CHIRAL AND ACHIRAL SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND THEIR DERIVATIVES | COR THERAPEUTICS INC (US) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001092249-A2 | CHIRAL AND ACHIRAL SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND THEIR DERIVATIVES | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044225-A1 | Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives | ACAT2, ACACA, COASY | CA2 57/4885HTR1A 1532/4885SIGMAR1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.